CATALOGO DEI PRODOTTI DELLA RICERCA

PERTILE, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.504
NA - Nord America 2.250
AS - Asia 1.319
SA - Sud America 189
AF - Africa 36
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.305
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.211
RU - Federazione Russa 786
GB - Regno Unito 526
SG - Singapore 518
IT - Italia 455
CN - Cina 442
BR - Brasile 162
HK - Hong Kong 156
DE - Germania 149
FR - Francia 141
IE - Irlanda 118
SE - Svezia 117
FI - Finlandia 95
VN - Vietnam 64
KR - Corea 33
UA - Ucraina 26
CA - Canada 24
IN - India 18
NL - Olanda 15
BD - Bangladesh 14
BE - Belgio 14
ES - Italia 12
PL - Polonia 12
ID - Indonesia 11
TR - Turchia 11
EC - Ecuador 10
JP - Giappone 9
TG - Togo 9
PT - Portogallo 8
MX - Messico 7
SA - Arabia Saudita 7
AR - Argentina 6
AT - Austria 6
BJ - Benin 6
CZ - Repubblica Ceca 6
IQ - Iraq 6
ZA - Sudafrica 6
AU - Australia 5
IR - Iran 5
CO - Colombia 4
EG - Egitto 4
GR - Grecia 4
AL - Albania 3
DK - Danimarca 3
KZ - Kazakistan 3
MA - Marocco 3
SY - Repubblica araba siriana 3
UG - Uganda 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
CH - Svizzera 2
CL - Cile 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
JO - Giordania 2
PY - Paraguay 2
TH - Thailandia 2
TW - Taiwan 2
AO - Angola 1
AZ - Azerbaigian 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
LY - Libia 1
MT - Malta 1
MY - Malesia 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 6.305
Salva come PNG Salva come JPEG
Città #
Southend 437
Dallas 317
Chandler 308
Moscow 250
Singapore 226
Woodbridge 198
Ann Arbor 166
Jacksonville 163
Ashburn 162
Hong Kong 151
Dublin 113
Verona 103
Beijing 64
Padova 56
Los Angeles 47
Princeton 46
Milan 45
Lawrence 44
Munich 43
Wilmington 41
Houston 39
New York 38
Helsinki 33
The Dalles 32
Nanjing 31
Shenyang 28
Jinan 25
Tianjin 25
Buffalo 23
Ho Chi Minh City 18
São Paulo 18
Boardman 17
Zhengzhou 16
Brussels 14
Columbus 14
Hanoi 14
Hebei 14
Lancaster 14
Guangzhou 13
Montreal 13
Sindelfingen 13
Taiyuan 13
London 12
Redondo Beach 12
Santa Clara 12
Warsaw 12
Haikou 11
Hangzhou 11
Falkenstein 10
Ningbo 10
Phoenix 10
Seattle 10
Jakarta 9
Jiaxing 9
Lomé 9
Norwalk 9
Redmond 9
Roverbella 9
San Francisco 9
Stockholm 9
Taizhou 9
Atlanta 8
Changsha 8
Chennai 8
Denver 8
Tokyo 8
Afragola 7
Chicago 7
Dong Ket 7
Meda 7
Nanchang 7
Rome 7
Ankara 6
Belluno 6
Belo Horizonte 6
Boston 6
Cotonou 6
Frankfurt am Main 6
Lanzhou 6
Limena 6
Lonigo 6
Riyadh 6
Romola 6
Venice 6
Washington 6
Ballyvaghan 5
Bari 5
Brooklyn 5
Dearborn 5
Guayaquil 5
Johannesburg 5
Poplar 5
San Giovanni Lupatoto 5
Secaucus 5
Auburn Hills 4
Campinas 4
Fairfield 4
Garbagnate Milanese 4
Manchester 4
Maple 4
Totale 3.865
Salva come PNG Salva come JPEG
Nome #
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 216
A Large Scale OLG Model for the Analysis of the Redistributive Effects of Policy Reforms 215
R&D and market size: who benefits from orphan drug regulation? 194
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 182
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies 178
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 177
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919) 162
Redistribution at the Local Level: The Case of Public Childcare in Italy 159
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919) 149
DRGs: the link between investment in technologies and appropriateness. WP Series University of Verona Department of Economics (ISSN 2036-2919), 31/2012 148
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 144
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011 143
Investimenti pubblici, risorse scarse: il ruolo dei diversi metodi di supporto alle decisioni 141
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry 139
Job Sick Leave: Detecting Opportunistic Behavior 139
Public finance consolidation and fairness across living generations: the case of Italy. WP Series University of Verona Department of Economics (ISSN 2036-2919), 04/2012 138
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 129
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysis 126
A stepped-wedge randomised controlled trial to assess efficacy and cost-effectiveness of a care-bundle to prevent falls in older hospitalised patients 121
The timing of adoption of positron emission tomography:a real options approach 120
Improving access to medicines and promoting pharmaceutical innovation 119
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial 118
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012 117
Efficienza e sostenibilità dell’intervento pubblico 116
A reply to "Who would benefit from average value-based pricing?" 114
Dynamic, incentive-compatible contracting for health services 114
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 113
Investment in health technologies in a competitive model with real options 109
Two-part payments for the reimbursement of investments in health technologies 109
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 109
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 109
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy 108
Optimal Decision Rules for HTA Under Uncertainty: a Wider, Dynamic Perspective 107
The dynamics of pharmaceutical regulation and R&D investments 107
Optimal sequential sampling rules for the economic evaluation of health technologies 103
The fiscal disadvantage of young italians: a new view on consolidation and fairness 103
Who should monitor job sick leave? 102
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial 101
The impact of managed entry agreements on pharmaceutical prices 100
Strategic Interaction in Pharmaceutical Price Regulation: With or Without U? 99
Pricing policies when patients are heterogeneous: a welfare analysis 99
Technology adoption, quality and health care costs: a review of the literature 98
Which valued-based price when patients are heterogeneous? 98
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 97
R&D and market size: who benefits from orphan drug legislation? 96
Static and dynamic effciency of irreversible health care investments under alternative payment rules 90
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" 88
L’equità intergenerazionale delle politiche di bilancio 83
Static and Dynamic Efficiency of Irreversible Health Care investments under Alternative Payment Rules 81
Public health interventions: evaluating the economic evaluations 79
Valutare l’efficienza dei servizi ospedalieri in Italia: il caso delle aziende ospedaliero-universitarie 63
Optimal Sequential Sampling with Delayed Observations and Unknown Variance 63
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 54
Totale 6.386
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.366
article - articoli 10.917
book - libri 0
conference - conferenze 346
curatela - curatele 407
other - altro 8.198
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.498
Totale 42.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021194 0 0 0 0 40 32 6 18 40 13 26 19
2021/2022422 30 70 13 6 19 17 18 25 41 13 66 104
2022/2023804 60 96 72 122 76 194 7 53 84 12 24 4
2023/2024435 18 30 31 72 47 57 27 38 10 16 53 36
2024/20251.183 57 90 67 195 32 32 31 102 162 82 103 230
2025/20261.937 218 177 331 568 643 0 0 0 0 0 0 0
Totale 6.386